Compare iShares China Large-Cap ETF (FXI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares China Large-Cap ETF trades at $34.51, while Regeneron Pharmaceuticals Inc trades at $678.68 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while iShares China Large-Cap ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | REGN | |
|---|---|---|
52-Week High | $41.75 | $812.27 |
52-Week Low | $31.59 | $542.52 |
Market Cap | — | $69.66B |
Sector | — | Health |
Enterprise Value | — | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI is currently trading at $34.545, up 2.29% with strong technical momentum indicated by bullish moving averages and ADX signals. The ETF benefits from China's accelerating AI and manufacturing sectors, with recent news highlighting a $295 billion AI infrastructure plan and robust export growth. However, RSI readings above 89 suggest the ETF is significantly overbought near-term.
The outlook remains positive given China's strategic investments in technology and manufacturing, though investors face risks from US-China trade tensions and potential profit-taking after recent gains. Wall Street sentiment is cautiously optimistic as institutional flows respond to China's economic initiatives.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
